A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Identifieur interne : 002055 ( PubMed/Curation ); précédent : 002054; suivant : 002056A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Auteurs : A C Rawstron [Royaume-Uni] ; C. Fazi [Italie] ; A. Agathangelidis [Italie] ; N. Villamor [Espagne] ; R. Letestu [France] ; J. Nomdedeu [Espagne] ; C. Palacio [Espagne] ; O. Stehlikova [République tchèque] ; K-A Kreuzer [Allemagne] ; S. Liptrot [Irlande (pays)] ; D. O'Brien [Irlande (pays)] ; R M De Tute [Royaume-Uni] ; I. Marinov [République tchèque] ; M. Hauwel [Suisse] ; M. Spacek [République tchèque] ; J. Dobber [Pays-Bas] ; A P Kater [Pays-Bas] ; P. Gambell [Australie] ; A. Soosapilla [Australie] ; G. Lozanski [États-Unis] ; G. Brachtl [Autriche] ; K. Lin [Royaume-Uni] ; J. Boysen [États-Unis] ; C. Hanson [États-Unis] ; J L Jorgensen [États-Unis] ; M. Stetler-Stevenson [États-Unis] ; C. Yuan [États-Unis] ; H E Broome [États-Unis] ; L. Rassenti [États-Unis] ; F. Craig [États-Unis] ; J. Delgado [Espagne] ; C. Moreno [Espagne] ; F. Bosch [Espagne] ; A. Egle [Autriche] ; M. Doubek [République tchèque] ; S. Pospisilova [République tchèque] ; S. Mulligan [Australie] ; D. Westerman [Australie] ; C M Sanders [États-Unis] ; R. Emerson [États-Unis] ; H S Robins [États-Unis] ; I. Kirsch [États-Unis] ; T. Shanafelt [États-Unis] ; A. Pettitt [Royaume-Uni] ; T J Kipps [États-Unis] ; W G Wierda [États-Unis] ; F. Cymbalista [France] ; M. Hallek [Allemagne] ; P. Hillmen [Royaume-Uni] ; E. Montserrat [Espagne] ; P. Ghia [Italie]Source :
- Leukemia [ 1476-5551 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Antigènes CD (métabolisme), Association thérapeutique, Cytométrie en flux (normes), Europe, Femelle, Humains, Immunophénotypage, Jeune adulte, Leucémie chronique lymphocytaire à cellules B (), Leucémie chronique lymphocytaire à cellules B (anatomopathologie), Maladie résiduelle (diagnostic), Maladie résiduelle (génétique), Maladie résiduelle (métabolisme), Mâle, Pronostic, Stade de la tumeur, Séquençage nucléotidique à haut débit (), Études de suivi.
- MESH :
- anatomopathologie : Leucémie chronique lymphocytaire à cellules B.
- diagnostic : Maladie résiduelle.
- génétique : Maladie résiduelle.
- métabolisme : Antigènes CD, Maladie résiduelle.
- normes : Cytométrie en flux.
- Adolescent, Adulte, Association thérapeutique, Europe, Femelle, Humains, Immunophénotypage, Jeune adulte, Leucémie chronique lymphocytaire à cellules B, Mâle, Pronostic, Stade de la tumeur, Séquençage nucléotidique à haut débit, Études de suivi.
English descriptors
- KwdEn :
- Adolescent, Adult, Antigens, CD (metabolism), Combined Modality Therapy, Europe, Female, Flow Cytometry (standards), Follow-Up Studies, High-Throughput Nucleotide Sequencing (methods), Humans, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell (pathology), Leukemia, Lymphocytic, Chronic, B-Cell (therapy), Male, Neoplasm Staging, Neoplasm, Residual (diagnosis), Neoplasm, Residual (genetics), Neoplasm, Residual (metabolism), Prognosis, Young Adult.
- MESH :
- chemical , metabolism : Antigens, CD.
- geographic : Europe.
- diagnosis : Neoplasm, Residual.
- genetics : Neoplasm, Residual.
- metabolism : Neoplasm, Residual.
- methods : High-Throughput Nucleotide Sequencing.
- pathology : Leukemia, Lymphocytic, Chronic, B-Cell.
- standards : Flow Cytometry.
- therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- Adolescent, Adult, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Immunophenotyping, Male, Neoplasm Staging, Prognosis, Young Adult.
Abstract
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.
DOI: 10.1038/leu.2015.313
PubMed: 26639181
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002080
Links to Exploration step
pubmed:26639181Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.</title><author><name sortKey="Rawstron, A C" sort="Rawstron, A C" uniqKey="Rawstron A" first="A C" last="Rawstron">A C Rawstron</name><affiliation wicri:level="1"><nlm:affiliation>HMDS, St James's Institute of Oncology, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>HMDS, St James's Institute of Oncology, Leeds</wicri:regionArea></affiliation></author><author><name sortKey="Fazi, C" sort="Fazi, C" uniqKey="Fazi C" first="C" last="Fazi">C. Fazi</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS San Raffaele Scientific Institute, Milano</wicri:regionArea></affiliation></author><author><name sortKey="Agathangelidis, A" sort="Agathangelidis, A" uniqKey="Agathangelidis A" first="A" last="Agathangelidis">A. Agathangelidis</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS San Raffaele Scientific Institute, Milano</wicri:regionArea></affiliation></author><author><name sortKey="Villamor, N" sort="Villamor, N" uniqKey="Villamor N" first="N" last="Villamor">N. Villamor</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínic, IDIBAPS, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Letestu, R" sort="Letestu, R" uniqKey="Letestu R" first="R" last="Letestu">R. Letestu</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny</wicri:regionArea></affiliation></author><author><name sortKey="Nomdedeu, J" sort="Nomdedeu, J" uniqKey="Nomdedeu J" first="J" last="Nomdedeu">J. Nomdedeu</name><affiliation wicri:level="1"><nlm:affiliation>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital de la Santa Creu i Sant Pau, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Palacio, C" sort="Palacio, C" uniqKey="Palacio C" first="C" last="Palacio">C. Palacio</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitari Vall d'Hebron, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari Vall d'Hebron, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Stehlikova, O" sort="Stehlikova, O" uniqKey="Stehlikova O" first="O" last="Stehlikova">O. Stehlikova</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno</wicri:regionArea></affiliation></author><author><name sortKey="Kreuzer, K A" sort="Kreuzer, K A" uniqKey="Kreuzer K" first="K-A" last="Kreuzer">K-A Kreuzer</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Liptrot, S" sort="Liptrot, S" uniqKey="Liptrot S" first="S" last="Liptrot">S. Liptrot</name><affiliation wicri:level="1"><nlm:affiliation>St James Hospital, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>St James Hospital, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="O Brien, D" sort="O Brien, D" uniqKey="O Brien D" first="D" last="O'Brien">D. O'Brien</name><affiliation wicri:level="1"><nlm:affiliation>St James Hospital, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>St James Hospital, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="De Tute, R M" sort="De Tute, R M" uniqKey="De Tute R" first="R M" last="De Tute">R M De Tute</name><affiliation wicri:level="1"><nlm:affiliation>HMDS, St James's Institute of Oncology, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>HMDS, St James's Institute of Oncology, Leeds</wicri:regionArea></affiliation></author><author><name sortKey="Marinov, I" sort="Marinov, I" uniqKey="Marinov I" first="I" last="Marinov">I. Marinov</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague</wicri:regionArea></affiliation></author><author><name sortKey="Hauwel, M" sort="Hauwel, M" uniqKey="Hauwel M" first="M" last="Hauwel">M. Hauwel</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Geneva, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University Hospital Geneva, Geneva</wicri:regionArea></affiliation></author><author><name sortKey="Spacek, M" sort="Spacek, M" uniqKey="Spacek M" first="M" last="Spacek">M. Spacek</name><affiliation wicri:level="1"><nlm:affiliation>General University Hospital, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>General University Hospital, Prague</wicri:regionArea></affiliation></author><author><name sortKey="Dobber, J" sort="Dobber, J" uniqKey="Dobber J" first="J" last="Dobber">J. Dobber</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hematology, Academic Medical Centre, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Kater, A P" sort="Kater, A P" uniqKey="Kater A" first="A P" last="Kater">A P Kater</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hematology, Academic Medical Centre, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Gambell, P" sort="Gambell, P" uniqKey="Gambell P" first="P" last="Gambell">P. Gambell</name><affiliation wicri:level="1"><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Soosapilla, A" sort="Soosapilla, A" uniqKey="Soosapilla A" first="A" last="Soosapilla">A. Soosapilla</name><affiliation wicri:level="1"><nlm:affiliation>Hematology and Flow Cytometry, Laverty Pathology, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Hematology and Flow Cytometry, Laverty Pathology, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Lozanski, G" sort="Lozanski, G" uniqKey="Lozanski G" first="G" last="Lozanski">G. Lozanski</name><affiliation wicri:level="1"><nlm:affiliation>Ohio State University Medical Center, Columbus, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Ohio State University Medical Center, Columbus, OH</wicri:regionArea></affiliation></author><author><name sortKey="Brachtl, G" sort="Brachtl, G" uniqKey="Brachtl G" first="G" last="Brachtl">G. Brachtl</name><affiliation wicri:level="1"><nlm:affiliation>3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>3rd Medical Department, Paracelsus Medical University, Salzburg</wicri:regionArea></affiliation></author><author><name sortKey="Lin, K" sort="Lin, K" uniqKey="Lin K" first="K" last="Lin">K. Lin</name><affiliation wicri:level="1"><nlm:affiliation>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Boysen, J" sort="Boysen, J" uniqKey="Boysen J" first="J" last="Boysen">J. Boysen</name><affiliation wicri:level="1"><nlm:affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Hanson, C" sort="Hanson, C" uniqKey="Hanson C" first="C" last="Hanson">C. Hanson</name><affiliation wicri:level="1"><nlm:affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Jorgensen, J L" sort="Jorgensen, J L" uniqKey="Jorgensen J" first="J L" last="Jorgensen">J L Jorgensen</name><affiliation wicri:level="1"><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Stetler Stevenson, M" sort="Stetler Stevenson, M" uniqKey="Stetler Stevenson M" first="M" last="Stetler-Stevenson">M. Stetler-Stevenson</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Yuan, C" sort="Yuan, C" uniqKey="Yuan C" first="C" last="Yuan">C. Yuan</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Broome, H E" sort="Broome, H E" uniqKey="Broome H" first="H E" last="Broome">H E Broome</name><affiliation wicri:level="1"><nlm:affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moores Cancer Center, University of California, San Diego, La Jolla, CA</wicri:regionArea></affiliation></author><author><name sortKey="Rassenti, L" sort="Rassenti, L" uniqKey="Rassenti L" first="L" last="Rassenti">L. Rassenti</name><affiliation wicri:level="1"><nlm:affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moores Cancer Center, University of California, San Diego, La Jolla, CA</wicri:regionArea></affiliation></author><author><name sortKey="Craig, F" sort="Craig, F" uniqKey="Craig F" first="F" last="Craig">F. Craig</name><affiliation wicri:level="1"><nlm:affiliation>Un1iversity of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Un1iversity of Pittsburgh, Pittsburgh, PA</wicri:regionArea></affiliation></author><author><name sortKey="Delgado, J" sort="Delgado, J" uniqKey="Delgado J" first="J" last="Delgado">J. Delgado</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínic, IDIBAPS, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Moreno, C" sort="Moreno, C" uniqKey="Moreno C" first="C" last="Moreno">C. Moreno</name><affiliation wicri:level="1"><nlm:affiliation>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital de la Santa Creu i Sant Pau, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Bosch, F" sort="Bosch, F" uniqKey="Bosch F" first="F" last="Bosch">F. Bosch</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitari Vall d'Hebron, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari Vall d'Hebron, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Egle, A" sort="Egle, A" uniqKey="Egle A" first="A" last="Egle">A. Egle</name><affiliation wicri:level="1"><nlm:affiliation>3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>3rd Medical Department, Paracelsus Medical University, Salzburg</wicri:regionArea></affiliation></author><author><name sortKey="Doubek, M" sort="Doubek, M" uniqKey="Doubek M" first="M" last="Doubek">M. Doubek</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno</wicri:regionArea></affiliation></author><author><name sortKey="Pospisilova, S" sort="Pospisilova, S" uniqKey="Pospisilova S" first="S" last="Pospisilova">S. Pospisilova</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno</wicri:regionArea></affiliation></author><author><name sortKey="Mulligan, S" sort="Mulligan, S" uniqKey="Mulligan S" first="S" last="Mulligan">S. Mulligan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Royal North Shore Hospital, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Westerman, D" sort="Westerman, D" uniqKey="Westerman D" first="D" last="Westerman">D. Westerman</name><affiliation wicri:level="1"><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Sanders, C M" sort="Sanders, C M" uniqKey="Sanders C" first="C M" last="Sanders">C M Sanders</name><affiliation wicri:level="1"><nlm:affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adaptive Biotechnologies, Seattle, WA</wicri:regionArea></affiliation></author><author><name sortKey="Emerson, R" sort="Emerson, R" uniqKey="Emerson R" first="R" last="Emerson">R. Emerson</name><affiliation wicri:level="1"><nlm:affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adaptive Biotechnologies, Seattle, WA</wicri:regionArea></affiliation></author><author><name sortKey="Robins, H S" sort="Robins, H S" uniqKey="Robins H" first="H S" last="Robins">H S Robins</name><affiliation wicri:level="1"><nlm:affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adaptive Biotechnologies, Seattle, WA</wicri:regionArea></affiliation></author><author><name sortKey="Kirsch, I" sort="Kirsch, I" uniqKey="Kirsch I" first="I" last="Kirsch">I. Kirsch</name><affiliation wicri:level="1"><nlm:affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adaptive Biotechnologies, Seattle, WA</wicri:regionArea></affiliation></author><author><name sortKey="Shanafelt, T" sort="Shanafelt, T" uniqKey="Shanafelt T" first="T" last="Shanafelt">T. Shanafelt</name><affiliation wicri:level="1"><nlm:affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Pettitt, A" sort="Pettitt, A" uniqKey="Pettitt A" first="A" last="Pettitt">A. Pettitt</name><affiliation wicri:level="1"><nlm:affiliation>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Kipps, T J" sort="Kipps, T J" uniqKey="Kipps T" first="T J" last="Kipps">T J Kipps</name><affiliation wicri:level="1"><nlm:affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moores Cancer Center, University of California, San Diego, La Jolla, CA</wicri:regionArea></affiliation></author><author><name sortKey="Wierda, W G" sort="Wierda, W G" uniqKey="Wierda W" first="W G" last="Wierda">W G Wierda</name><affiliation wicri:level="1"><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Cymbalista, F" sort="Cymbalista, F" uniqKey="Cymbalista F" first="F" last="Cymbalista">F. Cymbalista</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny</wicri:regionArea></affiliation></author><author><name sortKey="Hallek, M" sort="Hallek, M" uniqKey="Hallek M" first="M" last="Hallek">M. Hallek</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Hillmen, P" sort="Hillmen, P" uniqKey="Hillmen P" first="P" last="Hillmen">P. Hillmen</name><affiliation wicri:level="1"><nlm:affiliation>Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Leeds Institute of Cancer and Pathology, University of Leeds, Leeds</wicri:regionArea></affiliation></author><author><name sortKey="Montserrat, E" sort="Montserrat, E" uniqKey="Montserrat E" first="E" last="Montserrat">E. Montserrat</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínic, IDIBAPS, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Ghia, P" sort="Ghia, P" uniqKey="Ghia P" first="P" last="Ghia">P. Ghia</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS San Raffaele Scientific Institute, Milano</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26639181</idno><idno type="pmid">26639181</idno><idno type="doi">10.1038/leu.2015.313</idno><idno type="wicri:Area/PubMed/Corpus">002080</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002080</idno><idno type="wicri:Area/PubMed/Curation">002055</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002055</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.</title><author><name sortKey="Rawstron, A C" sort="Rawstron, A C" uniqKey="Rawstron A" first="A C" last="Rawstron">A C Rawstron</name><affiliation wicri:level="1"><nlm:affiliation>HMDS, St James's Institute of Oncology, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>HMDS, St James's Institute of Oncology, Leeds</wicri:regionArea></affiliation></author><author><name sortKey="Fazi, C" sort="Fazi, C" uniqKey="Fazi C" first="C" last="Fazi">C. Fazi</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS San Raffaele Scientific Institute, Milano</wicri:regionArea></affiliation></author><author><name sortKey="Agathangelidis, A" sort="Agathangelidis, A" uniqKey="Agathangelidis A" first="A" last="Agathangelidis">A. Agathangelidis</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS San Raffaele Scientific Institute, Milano</wicri:regionArea></affiliation></author><author><name sortKey="Villamor, N" sort="Villamor, N" uniqKey="Villamor N" first="N" last="Villamor">N. Villamor</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínic, IDIBAPS, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Letestu, R" sort="Letestu, R" uniqKey="Letestu R" first="R" last="Letestu">R. Letestu</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny</wicri:regionArea></affiliation></author><author><name sortKey="Nomdedeu, J" sort="Nomdedeu, J" uniqKey="Nomdedeu J" first="J" last="Nomdedeu">J. Nomdedeu</name><affiliation wicri:level="1"><nlm:affiliation>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital de la Santa Creu i Sant Pau, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Palacio, C" sort="Palacio, C" uniqKey="Palacio C" first="C" last="Palacio">C. Palacio</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitari Vall d'Hebron, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari Vall d'Hebron, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Stehlikova, O" sort="Stehlikova, O" uniqKey="Stehlikova O" first="O" last="Stehlikova">O. Stehlikova</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno</wicri:regionArea></affiliation></author><author><name sortKey="Kreuzer, K A" sort="Kreuzer, K A" uniqKey="Kreuzer K" first="K-A" last="Kreuzer">K-A Kreuzer</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Liptrot, S" sort="Liptrot, S" uniqKey="Liptrot S" first="S" last="Liptrot">S. Liptrot</name><affiliation wicri:level="1"><nlm:affiliation>St James Hospital, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>St James Hospital, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="O Brien, D" sort="O Brien, D" uniqKey="O Brien D" first="D" last="O'Brien">D. O'Brien</name><affiliation wicri:level="1"><nlm:affiliation>St James Hospital, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>St James Hospital, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="De Tute, R M" sort="De Tute, R M" uniqKey="De Tute R" first="R M" last="De Tute">R M De Tute</name><affiliation wicri:level="1"><nlm:affiliation>HMDS, St James's Institute of Oncology, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>HMDS, St James's Institute of Oncology, Leeds</wicri:regionArea></affiliation></author><author><name sortKey="Marinov, I" sort="Marinov, I" uniqKey="Marinov I" first="I" last="Marinov">I. Marinov</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague</wicri:regionArea></affiliation></author><author><name sortKey="Hauwel, M" sort="Hauwel, M" uniqKey="Hauwel M" first="M" last="Hauwel">M. Hauwel</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Geneva, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University Hospital Geneva, Geneva</wicri:regionArea></affiliation></author><author><name sortKey="Spacek, M" sort="Spacek, M" uniqKey="Spacek M" first="M" last="Spacek">M. Spacek</name><affiliation wicri:level="1"><nlm:affiliation>General University Hospital, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>General University Hospital, Prague</wicri:regionArea></affiliation></author><author><name sortKey="Dobber, J" sort="Dobber, J" uniqKey="Dobber J" first="J" last="Dobber">J. Dobber</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hematology, Academic Medical Centre, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Kater, A P" sort="Kater, A P" uniqKey="Kater A" first="A P" last="Kater">A P Kater</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hematology, Academic Medical Centre, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Gambell, P" sort="Gambell, P" uniqKey="Gambell P" first="P" last="Gambell">P. Gambell</name><affiliation wicri:level="1"><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Soosapilla, A" sort="Soosapilla, A" uniqKey="Soosapilla A" first="A" last="Soosapilla">A. Soosapilla</name><affiliation wicri:level="1"><nlm:affiliation>Hematology and Flow Cytometry, Laverty Pathology, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Hematology and Flow Cytometry, Laverty Pathology, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Lozanski, G" sort="Lozanski, G" uniqKey="Lozanski G" first="G" last="Lozanski">G. Lozanski</name><affiliation wicri:level="1"><nlm:affiliation>Ohio State University Medical Center, Columbus, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Ohio State University Medical Center, Columbus, OH</wicri:regionArea></affiliation></author><author><name sortKey="Brachtl, G" sort="Brachtl, G" uniqKey="Brachtl G" first="G" last="Brachtl">G. Brachtl</name><affiliation wicri:level="1"><nlm:affiliation>3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>3rd Medical Department, Paracelsus Medical University, Salzburg</wicri:regionArea></affiliation></author><author><name sortKey="Lin, K" sort="Lin, K" uniqKey="Lin K" first="K" last="Lin">K. Lin</name><affiliation wicri:level="1"><nlm:affiliation>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Boysen, J" sort="Boysen, J" uniqKey="Boysen J" first="J" last="Boysen">J. Boysen</name><affiliation wicri:level="1"><nlm:affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Hanson, C" sort="Hanson, C" uniqKey="Hanson C" first="C" last="Hanson">C. Hanson</name><affiliation wicri:level="1"><nlm:affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Jorgensen, J L" sort="Jorgensen, J L" uniqKey="Jorgensen J" first="J L" last="Jorgensen">J L Jorgensen</name><affiliation wicri:level="1"><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Stetler Stevenson, M" sort="Stetler Stevenson, M" uniqKey="Stetler Stevenson M" first="M" last="Stetler-Stevenson">M. Stetler-Stevenson</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Yuan, C" sort="Yuan, C" uniqKey="Yuan C" first="C" last="Yuan">C. Yuan</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Broome, H E" sort="Broome, H E" uniqKey="Broome H" first="H E" last="Broome">H E Broome</name><affiliation wicri:level="1"><nlm:affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moores Cancer Center, University of California, San Diego, La Jolla, CA</wicri:regionArea></affiliation></author><author><name sortKey="Rassenti, L" sort="Rassenti, L" uniqKey="Rassenti L" first="L" last="Rassenti">L. Rassenti</name><affiliation wicri:level="1"><nlm:affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moores Cancer Center, University of California, San Diego, La Jolla, CA</wicri:regionArea></affiliation></author><author><name sortKey="Craig, F" sort="Craig, F" uniqKey="Craig F" first="F" last="Craig">F. Craig</name><affiliation wicri:level="1"><nlm:affiliation>Un1iversity of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Un1iversity of Pittsburgh, Pittsburgh, PA</wicri:regionArea></affiliation></author><author><name sortKey="Delgado, J" sort="Delgado, J" uniqKey="Delgado J" first="J" last="Delgado">J. Delgado</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínic, IDIBAPS, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Moreno, C" sort="Moreno, C" uniqKey="Moreno C" first="C" last="Moreno">C. Moreno</name><affiliation wicri:level="1"><nlm:affiliation>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital de la Santa Creu i Sant Pau, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Bosch, F" sort="Bosch, F" uniqKey="Bosch F" first="F" last="Bosch">F. Bosch</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitari Vall d'Hebron, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari Vall d'Hebron, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Egle, A" sort="Egle, A" uniqKey="Egle A" first="A" last="Egle">A. Egle</name><affiliation wicri:level="1"><nlm:affiliation>3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>3rd Medical Department, Paracelsus Medical University, Salzburg</wicri:regionArea></affiliation></author><author><name sortKey="Doubek, M" sort="Doubek, M" uniqKey="Doubek M" first="M" last="Doubek">M. Doubek</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno</wicri:regionArea></affiliation></author><author><name sortKey="Pospisilova, S" sort="Pospisilova, S" uniqKey="Pospisilova S" first="S" last="Pospisilova">S. Pospisilova</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno</wicri:regionArea></affiliation></author><author><name sortKey="Mulligan, S" sort="Mulligan, S" uniqKey="Mulligan S" first="S" last="Mulligan">S. Mulligan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Royal North Shore Hospital, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Westerman, D" sort="Westerman, D" uniqKey="Westerman D" first="D" last="Westerman">D. Westerman</name><affiliation wicri:level="1"><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Sanders, C M" sort="Sanders, C M" uniqKey="Sanders C" first="C M" last="Sanders">C M Sanders</name><affiliation wicri:level="1"><nlm:affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adaptive Biotechnologies, Seattle, WA</wicri:regionArea></affiliation></author><author><name sortKey="Emerson, R" sort="Emerson, R" uniqKey="Emerson R" first="R" last="Emerson">R. Emerson</name><affiliation wicri:level="1"><nlm:affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adaptive Biotechnologies, Seattle, WA</wicri:regionArea></affiliation></author><author><name sortKey="Robins, H S" sort="Robins, H S" uniqKey="Robins H" first="H S" last="Robins">H S Robins</name><affiliation wicri:level="1"><nlm:affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adaptive Biotechnologies, Seattle, WA</wicri:regionArea></affiliation></author><author><name sortKey="Kirsch, I" sort="Kirsch, I" uniqKey="Kirsch I" first="I" last="Kirsch">I. Kirsch</name><affiliation wicri:level="1"><nlm:affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adaptive Biotechnologies, Seattle, WA</wicri:regionArea></affiliation></author><author><name sortKey="Shanafelt, T" sort="Shanafelt, T" uniqKey="Shanafelt T" first="T" last="Shanafelt">T. Shanafelt</name><affiliation wicri:level="1"><nlm:affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Pettitt, A" sort="Pettitt, A" uniqKey="Pettitt A" first="A" last="Pettitt">A. Pettitt</name><affiliation wicri:level="1"><nlm:affiliation>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Kipps, T J" sort="Kipps, T J" uniqKey="Kipps T" first="T J" last="Kipps">T J Kipps</name><affiliation wicri:level="1"><nlm:affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Moores Cancer Center, University of California, San Diego, La Jolla, CA</wicri:regionArea></affiliation></author><author><name sortKey="Wierda, W G" sort="Wierda, W G" uniqKey="Wierda W" first="W G" last="Wierda">W G Wierda</name><affiliation wicri:level="1"><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Cymbalista, F" sort="Cymbalista, F" uniqKey="Cymbalista F" first="F" last="Cymbalista">F. Cymbalista</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny</wicri:regionArea></affiliation></author><author><name sortKey="Hallek, M" sort="Hallek, M" uniqKey="Hallek M" first="M" last="Hallek">M. Hallek</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Hillmen, P" sort="Hillmen, P" uniqKey="Hillmen P" first="P" last="Hillmen">P. Hillmen</name><affiliation wicri:level="1"><nlm:affiliation>Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Leeds Institute of Cancer and Pathology, University of Leeds, Leeds</wicri:regionArea></affiliation></author><author><name sortKey="Montserrat, E" sort="Montserrat, E" uniqKey="Montserrat E" first="E" last="Montserrat">E. Montserrat</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínic, IDIBAPS, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Ghia, P" sort="Ghia, P" uniqKey="Ghia P" first="P" last="Ghia">P. Ghia</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS San Raffaele Scientific Institute, Milano</wicri:regionArea></affiliation></author></analytic><series><title level="j">Leukemia</title><idno type="eISSN">1476-5551</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Antigens, CD (metabolism)</term><term>Combined Modality Therapy</term><term>Europe</term><term>Female</term><term>Flow Cytometry (standards)</term><term>Follow-Up Studies</term><term>High-Throughput Nucleotide Sequencing (methods)</term><term>Humans</term><term>Immunophenotyping</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (pathology)</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (therapy)</term><term>Male</term><term>Neoplasm Staging</term><term>Neoplasm, Residual (diagnosis)</term><term>Neoplasm, Residual (genetics)</term><term>Neoplasm, Residual (metabolism)</term><term>Prognosis</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Antigènes CD (métabolisme)</term><term>Association thérapeutique</term><term>Cytométrie en flux (normes)</term><term>Europe</term><term>Femelle</term><term>Humains</term><term>Immunophénotypage</term><term>Jeune adulte</term><term>Leucémie chronique lymphocytaire à cellules B ()</term><term>Leucémie chronique lymphocytaire à cellules B (anatomopathologie)</term><term>Maladie résiduelle (diagnostic)</term><term>Maladie résiduelle (génétique)</term><term>Maladie résiduelle (métabolisme)</term><term>Mâle</term><term>Pronostic</term><term>Stade de la tumeur</term><term>Séquençage nucléotidique à haut débit ()</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antigens, CD</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neoplasm, Residual</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Maladie résiduelle</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Neoplasm, Residual</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Maladie résiduelle</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neoplasm, Residual</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>High-Throughput Nucleotide Sequencing</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antigènes CD</term><term>Maladie résiduelle</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Cytométrie en flux</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Flow Cytometry</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Combined Modality Therapy</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Immunophenotyping</term><term>Male</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Association thérapeutique</term><term>Europe</term><term>Femelle</term><term>Humains</term><term>Immunophénotypage</term><term>Jeune adulte</term><term>Leucémie chronique lymphocytaire à cellules B</term><term>Mâle</term><term>Pronostic</term><term>Stade de la tumeur</term><term>Séquençage nucléotidique à haut débit</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26639181</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>06</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.</ArticleTitle><Pagination><MedlinePgn>929-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2015.313</ELocationID><Abstract><AbstractText>In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rawstron</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>HMDS, St James's Institute of Oncology, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazi</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agathangelidis</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villamor</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letestu</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomdedeu</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palacio</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stehlikova</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreuzer</LastName><ForeName>K-A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>University Hospital, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liptrot</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>St James Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>St James Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Tute</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>HMDS, St James's Institute of Oncology, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinov</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauwel</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Hospital Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spacek</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General University Hospital, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobber</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kater</LastName><ForeName>A P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambell</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soosapilla</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hematology and Flow Cytometry, Laverty Pathology, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozanski</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ohio State University Medical Center, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brachtl</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental and Clinical Cell Therapy Institute, Spinal Cord and Tissue Regeneration Center, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boysen</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorgensen</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stetler-Stevenson</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broome</LastName><ForeName>H E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassenti</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Un1iversity of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egle</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doubek</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pospisilova</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulligan</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Haematology, Royal North Shore Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westerman</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emerson</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robins</LastName><ForeName>H S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirsch</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Adaptive Biotechnologies, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shanafelt</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettitt</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipps</LastName><ForeName>T J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wierda</LastName><ForeName>W G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cymbalista</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallek</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Hospital, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillmen</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montserrat</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital Clínic, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghia</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IRCCS San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Università Vita-Salute San Raffaele, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 CA081534</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Blood. 2001 Jul 1;98(1):29-35</RefSource><PMID Version="1">11418459</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Oct 2;376(9747):1164-74</RefSource><PMID Version="1">20888994</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2004 Aug 4;20 Suppl 1:i379-85</RefSource><PMID Version="1">15262823</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Mar 20;30(9):980-8</RefSource><PMID Version="1">22331940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2012 Sep;26(9):1908-75</RefSource><PMID Version="1">22552007</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Jan;27(1):142-9</RefSource><PMID Version="1">23041722</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cytometry B Clin Cytom. 2013 Mar;84(2):96-103</RefSource><PMID Version="1">23283845</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2013 May 30;121(22):4521-8</RefSource><PMID Version="1">23596047</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Aug;27(8):1659-65</RefSource><PMID Version="1">23419792</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cytometry B Clin Cytom. 2013 Sep-Oct;84(5):315-23</RefSource><PMID Version="1">24022854</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Lab Hematol. 2014 Apr;36(2):165-71</RefSource><PMID Version="1">24028768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2014 May;99(5):873-80</RefSource><PMID Version="1">24700492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 May 29;123(22):3390-7</RefSource><PMID Version="1">24615777</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Jun 12;123(24):3727-32</RefSource><PMID Version="1">24705492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Jul 17;371(3):213-23</RefSource><PMID Version="1">24881631</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood Cancer J. 2015;5:e273</RefSource><PMID Version="1">25615279</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 1994 Oct;8(10):1640-5</RefSource><PMID Version="1">7523797</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Feb 15;105(4):1678-85</RefSource><PMID Version="1">15466924</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 May 1;23(13):2884-5</RefSource><PMID Version="1">15738532</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 May 1;23(13):2971-9</RefSource><PMID Version="1">15738539</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2006 Jun 1;107(11):4563-9</RefSource><PMID Version="1">16449533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2006 Dec;20(12):2102-10</RefSource><PMID Version="1">17051247</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2007 May;21(5):956-64</RefSource><PMID Version="1">17361231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2008 Jan 15;14(2):396-404</RefSource><PMID Version="1">18223214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Jun 15;111(12):5446-56</RefSource><PMID Version="1">18216293</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Oct 15;112(8):3330-8</RefSource><PMID Version="1">18684859</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2009 Nov;23(11):2007-17</RefSource><PMID Version="1">19641522</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>In Silico Biol. 2004;4(1):17-29</RefSource><PMID Version="1">15089751</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018365" MajorTopicYN="N">Neoplasm, Residual</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4832072</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26639181</ArticleId><ArticleId IdType="pii">leu2015313</ArticleId><ArticleId IdType="doi">10.1038/leu.2015.313</ArticleId><ArticleId IdType="pmc">PMC4832072</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002055 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002055 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26639181
|texte= A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26639181" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |